Status
Conditions
Treatments
About
Breast cancer is the most common cancer among women. The morbidity and mortality of breast cancer are much higher than those observed with other female cancers (1). The incidence of breast cancer increases with age (2, 3). Approximately 1.7 million new cases are estimated to occur worldwide, and mortality is increasing in developing countries, primarily because the disease is not diagnosed until it is in an advanced stage(4) Neoadjuvant chemotherapy (NACT) is considered the standard of care for the management of locally advanced breast cancer and although this treatment has historically been reserved for those with inoperable breast cancer now is increasingly being used for women with earlier stage disease. (5). Encouraging results obtained with neoadjuvant chemotherapy in have resulted in clinicians using preoperative chemotherapy for patients with smaller tumors(6) . Neoadjuvant chemotherapy (NACT) could reduce surgical morbidity of the breast and axilla. By down staging of the tumor, NACT can convert patients who are candidates for mastectomy to breast-conserving surgery (BCS) candidates [7]. Furthermore, it has potential to reduce excision volumes in patients with large tumors who are already candidates for BCS. Another surgical advantage is down staging of the axilla so that axillary lymph node dissection can be avoided (8).
Complete pathological response after neoadjuvant systemic treatment is high, while complete clinical response rates are even higher. Because it is difficult to localize the original tumor bed after a complete clinical and radiological response, marking the tumor before the start of neoadjuvant systemic treatment is required to enable breast-conserving surgery afterward. Achieving adequate margins of excision is an important component of breast surgery. Local recurrence rates are significantly higher for patients who have positive margins of excision (9) some prospective and retrospective data suggested that patients with BCT after neoadjuvant therapy may have an increased risk for the development of a local recurrence .
If this were true, there would be no further advantage of neoadjuvant therapy and this treatment option could be questioned altogether.
A common question raised with respect to performing breast-conserving therapy after neoadjuvant chemotherapy is the volume of breast tissue that should be resected
Full description
Study subjects:
Inclusion criteria:
Exclusion criteria:
Sample Size Calculation:
Prospective trial study include 50 patient whom fulfilled the inclusion criteria 2.4.4 -Study tools (in detail, e.g., lab methods, instruments, steps, chemicals, ...): This prospective study is including patients will be diagnosed breast cancer and will receive neoadjuvant chemotherapy .
All patients underwent a preoperative clinical evaluation including physical examination (PE), ultrasonography, mammograph and MRI then biopsies of the breast tumor were performed to determine the histological subtype and receptor status Methods
Pro-operative preparation:
After confirming diagnosis of breast cancer and its molecular type patient undergoing marking the tumor and axillary lymph nodes by clips before receiving neoadjuvant chemotherapy.
Making Virtual pre-operative breast conserving surgical technique based on the previous tumor size
The Surgical steps:
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria:
a. Inclusion criteria:
Female patients with operable breast cancer
Female Patient aged from 20 to 60 years old
Patients who are fit for general anesthesia.
Patients who provide a written informed consent.
Patient who agree to provide short term outcome data and agree to provide contact information to provide contact information.
Exclusion Criteria:Exclusion criteria:
Primary purpose
Allocation
Interventional model
Masking
1 participants in 1 patient group
Loading...
Central trial contact
Samir Hosny, Master
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal